Vitamin D and Thyroid Cancer
Vitamin D is relevant in thyroid cancer care mainly for two reasons — post-thyroidectomy hypoparathyroidism (often needing active calcitriol rather than cholecalciferol) and TSH-suppression-related bone loss (needing standard vitamin D + calcium bone protection).
Post-thyroidectomy hypoparathyroidism
Total thyroidectomy for cancer can damage or remove parathyroid glands, causing transient (in ~25%) or permanent (~1-3%) hypoparathyroidism. PTH deficiency reduces intestinal calcium absorption and renal calcium reabsorption; standard cholecalciferol supplementation alone doesn't correct calcium adequately without PTH-driven activation. Active calcitriol (Rocaltrol) 0.25-0.5 µg BID plus calcium 1-2 g daily is standard replacement.
TSH suppression and bone loss
Differentiated thyroid cancer patients often receive TSH-suppressive levothyroxine doses to prevent recurrence. Long-term subclinical hyperthyroidism (suppressed TSH) accelerates bone loss, particularly in postmenopausal women. Standard vitamin D + calcium plus DEXA monitoring is standard care; bisphosphonate for osteopenia progression.
Does vitamin D prevent thyroid cancer?
Observational data are mixed. Some studies find lower 25(OH)D in thyroid cancer patients than controls; others find no association. There's no established preventive role. Vitamin D adequacy is general good practice, not a cancer-specific intervention.
Practical guide
- Post-thyroidectomy: calcium and PTH monitoring in the first weeks; calcitriol + calcium if hypoparathyroidism develops.
- Persistent hypoparathyroidism (> 6 months): endocrinology-managed with calcitriol titrated to normalise calcium.
- TSH-suppressed patients: 800-2,000 IU/day cholecalciferol, 1,000 mg/day calcium, DEXA at baseline and every 1-2 years.
- Standard maintenance in cancer survivorship: 1,000-2,000 IU/day.